Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03384875
Other study ID # 2017-001
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date April 19, 2018
Est. completion date January 18, 2022

Study information

Verified date August 2022
Source CytoSorbents, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective, multi-center, randomized, blinded, pivotal clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care plus treatment with the CytoSorb® device.


Recruitment information / eligibility

Status Terminated
Enrollment 116
Est. completion date January 18, 2022
Est. primary completion date January 18, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Scheduled for non-emergent cardiac surgery requiring CPB for i) heart valve replacement with any other procedure, without hypothermic circulatory arrest (HCA), or ii) aortic reconstruction with or without another procedure, with HCA Exclusion Criteria: - Isolated Coronary Artery Bypass Graft - Pregnant women - Life expectancy of < 14 days - End stage organ disease - Active infection - Correction of a congenital heart defect - Contraindication to anticoagulation with heparin - Minimally invasive surgery implantation (TAVI) or transcatheter aortic valve replacement (TAVR) - Declined informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Device:
CytoSorb
To evaluate the safety and performance of the CytoSorb® device to decrease the incidence or severity of acute kidney injury (AKI)

Locations

Country Name City State
United States University of Maryland Baltimore Maryland
United States Brigham and Women's Hospital Boston Massachusetts
United States University of Chicago Chicago Illinois
United States The Christ Hospital Linder Research Center Cincinnati Ohio
United States Ohio State university Columbus Ohio
United States Duke University Medical Center Durham North Carolina
United States East Carolina University Greenville North Carolina
United States Baylor College of Medicine Houston Texas
United States Indiana University Health Methodist Hospital Indianapolis Indiana
United States University of Louisville Louisville Kentucky
United States Baptist Memorial Hospital Memphis Tennessee
United States Vanderbilt University Nashville Tennessee
United States Yale School of Medicine New Haven Connecticut
United States Columbia University Medical Center New York New York
United States Northwell Health: Lennox Hill Hospital New York New York
United States Integris Baptist Medical Center Oklahoma City Oklahoma
United States University of Pennsylvania Philadelphia Pennsylvania
United States Maine Medical Center Portland Maine
United States Valley Hospital Ridgewood New Jersey
United States Iowa Heart Center West Des Moines Iowa

Sponsors (1)

Lead Sponsor Collaborator
CytoSorbents, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence or severity of acute kidney injury (AKI) in the first 48 hours after cardiopulmonary pulmonary bypass (CPB) Kidney Disease Improving Global Outcomes (KDIGO) definitions for AKI From start of CPB through 48 hours after CPB
Secondary Change in maximum plasma free hemoglobin and activated complement from start of CPB through post-surgery day 3 Blood sample indices of effects from cardiac surgery with CPB From start of CPB through post-surgery day 3
Secondary Severity or duration of AKI in the first 7 days after CPB KDIGO definitions for AKI From start of CPB through 7 days post-cardiac surgery
See also
  Status Clinical Trial Phase
Completed NCT02838524 - Acceptable Range of Inspiratory Effort During Mechanical Ventilation
Completed NCT02566525 - CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery N/A
Completed NCT00879931 - Influence of Corticoids on Renal Function in Cardiac Surgery Phase 2
Recruiting NCT05662501 - Pleiades Safety and Feasibility Study N/A
Completed NCT02407873 - Prognostic Impact of Frailty Assessed by Edmondon in Elderly Patient Undergoing Cardiac Surgery N/A
Not yet recruiting NCT01418521 - Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) After Cardiac Surgery Phase 4
Completed NCT01748266 - Microcirculation of the Thenar Eminence N/A